Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2022 11
2023 14
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Management of chronic myeloid leukemia in 2023 - common ground and common sense.
Senapati J, Sasaki K, Issa GC, Lipton JH, Radich JP, Jabbour E, Kantarjian HM. Senapati J, et al. Blood Cancer J. 2023 Apr 24;13(1):58. doi: 10.1038/s41408-023-00823-9. Blood Cancer J. 2023. PMID: 37088793 Free PMC article. Review.
Asciminib is a third-generation TKI with possibly a better toxicity profile, but lesser activity in T315I-mutated CML. Olverembatinib is another potent third-generation TKI with early promising results....
Asciminib is a third-generation TKI with possibly a better toxicity profile, but lesser activity in T315I-mutated CML. Olverembatinib …
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
Jabbour E, Kantarjian H. Jabbour E, et al. Am J Hematol. 2022 Sep;97(9):1236-1256. doi: 10.1002/ajh.26642. Epub 2022 Jul 6. Am J Hematol. 2022. PMID: 35751859 Free article.
Patients who develop the T315I "gatekeeper" mutation display resistance to all currently available TKIs except ponatinib, asciminib, and olverembatinib. Allogeneic stem cell transplantation remains an important therapeutic option for patients with CML-CP and failure (due t …
Patients who develop the T315I "gatekeeper" mutation display resistance to all currently available TKIs except ponatinib, asciminib, and …
Olverembatinib: First Approval.
Dhillon S. Dhillon S. Drugs. 2022 Mar;82(4):469-475. doi: 10.1007/s40265-022-01680-9. Drugs. 2022. PMID: 35195876 Review.
Olverembatinib is an ATP binding-site inhibitor of wild type BCR-ABL1 kinase and a broad spectrum of BCR-ABL1 mutants, including mutant T315I, which confers resistance against all first- and second-generation TKIs. ...This article summarizes the milestones in the developme …
Olverembatinib is an ATP binding-site inhibitor of wild type BCR-ABL1 kinase and a broad spectrum of BCR-ABL1 mutants, including muta …
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, Chen S, Liang Y, Hu Y, Liu X, Song Y, Men L, Chen Z, Niu Q, Wang H, Lu M, Yang D, Zhai Y, Huang X. Jiang Q, et al. J Hematol Oncol. 2022 Aug 18;15(1):113. doi: 10.1186/s13045-022-01334-z. J Hematol Oncol. 2022. PMID: 35982483 Free PMC article. Clinical Trial.
METHODS: In the phase 1 study, olverembatinib was orally administered once every other day in 28-day cycles at 11 dose cohorts ranging from 1 to 60 mg, and we evaluated the maximum tolerated dose, recommended phase 2 dose (RP2D), safety, efficacy, and pharmacokinetics of …
METHODS: In the phase 1 study, olverembatinib was orally administered once every other day in 28-day cycles at 11 dose cohorts rangin …
Olverembatinib Treatment in Pediatric Patients With Relapsed Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia.
Li X, Zhang J, Liu F, Liu T, Zhang R, Chen Y, Guo Y, Fang Y, Xu X, Pui CH, Zhu X. Li X, et al. Clin Lymphoma Myeloma Leuk. 2023 Sep;23(9):660-666. doi: 10.1016/j.clml.2023.04.012. Epub 2023 May 11. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37301632 Review.
The median duration of olverembatinib treatment was 70 days (range: 4-340) and the median cumulative dose was 600 mg (range: 80-3810). ...Safety profile in 6 evaluable patients was excellent with grade 2 extremity pain occurred in 2 patients and grade 2 myopathy of lower e …
The median duration of olverembatinib treatment was 70 days (range: 4-340) and the median cumulative dose was 600 mg (range: 80-3810) …
Olverembatinib in chronic myeloid leukemia.
Öziskender R, Eşkazan AE. Öziskender R, et al. Drugs Today (Barc). 2022 Nov;58(11):531-538. doi: 10.1358/dot.2022.58.11.3441854. Drugs Today (Barc). 2022. PMID: 36422514
In recent studies, olverembatinib appears to be an effective and safe treatment option for CML patients harboring T315I mutation. This article mainly focuses on the efficacy and safety data of olverembatinib along with other clinically available and potentially acti …
In recent studies, olverembatinib appears to be an effective and safe treatment option for CML patients harboring T315I mutation. Thi …
A review of the therapeutic role of the new third-generation TKI olverembatinib in chronic myeloid leukemia.
Qian H, Gang D, He X, Jiang S. Qian H, et al. Front Oncol. 2022 Dec 8;12:1036437. doi: 10.3389/fonc.2022.1036437. eCollection 2022. Front Oncol. 2022. PMID: 36568202 Free PMC article. Review.
Developing new drugs that target the T315I mutation will address the dilemma of treatment failure. Olverembatinib, as a third-generation TKI designed for the T315I mutation, is being researched in China. ...Herein, we review the characteristics and clinical trials of ol …
Developing new drugs that target the T315I mutation will address the dilemma of treatment failure. Olverembatinib, as a third-generat …
Management of Chronic Myeloid Leukemia Patients in Later Lines: The Role of Ponatinib and New Compounds.
Scalzulli E, Carmosino I, Costa A, Bisegna ML, Martelli M, Breccia M. Scalzulli E, et al. Clin Lymphoma Myeloma Leuk. 2023 Jun;23(6):420-425. doi: 10.1016/j.clml.2023.03.004. Epub 2023 Mar 20. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37029061 Review.
Unfortunately, a significant proportion of patients remain intolerant or refractory, making it crucial to develop new therapeutic options. Among these, novel agents such as vodobatinib and olverembatinib have provided promising result in clinical trials, representing valua …
Unfortunately, a significant proportion of patients remain intolerant or refractory, making it crucial to develop new therapeutic options. A …
Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes.
Hijiya N, Mauro MJ. Hijiya N, et al. Cancer Manag Res. 2023 Aug 23;15:873-891. doi: 10.2147/CMAR.S353374. eCollection 2023. Cancer Manag Res. 2023. PMID: 37641687 Free PMC article. Review.
In particular, the only previously available treatments for patients with CML-CP with the T315I mutation were ponatinib, olverembatinib (exclusively approved for use in China at the time of this writing), omacetaxine, and hematopoietic stem cell transplantation. ...
In particular, the only previously available treatments for patients with CML-CP with the T315I mutation were ponatinib, olverembatinib …
26 results